Clinical Trials
36 trialsAYAConnect
UNC Lineberger Comprehensive Cancer Center
HERO
Rutgers, The State University of New Jersey
ROOT
Taproot Health
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Eastern Cooperative Oncology Group
GASVERT
Institut de Cancérologie de Lorraine
A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy
Abramson Cancer Center at Penn Medicine
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
MacroGenics
ONCODAGE
Institut Bergonié
Effects of High-intensity Training Compared to Resistance Training in Cancer Patients Undergoing Radiotherapy
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
ADCC
National Cancer Institute (NCI)
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Stanford University
EPAC
Stanford University
Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer
Mayo Clinic
Spectroscopy With Surface Coils and Decoupling
Memorial Sloan Kettering Cancer Center
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
Duke University
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
National Cancer Institute (NCI)
HX4-200
Siemens Molecular Imaging
Chemotherapy in Treating Patients With Solid Tumors
Memorial Sloan Kettering Cancer Center
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
National Cancer Institute (NCI)
Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer
Vanderbilt-Ingram Cancer Center
Immunoreactivity to Cetuximab in Cancer Patients
Vanderbilt-Ingram Cancer Center
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Biological Therapy in Treating Patients With Metastatic Cancer
Duke University
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases
European Organisation for Research and Treatment of Cancer - EORTC
Gene Therapy in Treating Patients With Cancer
Roger Williams Medical Center
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
Light Sciences LLC